POINT Biopharma Reports Second Quarter 2022 Financial Results and Provides Business Highlights
12 août 2022 08h30 HE
|
POINT Biopharma
Additional data from the lead-in of PNT2002's SPLASH trial on track for fall 2022 release PNT6555, the lead of the pan-cancer PNT2004 fibroblast activation protein-alpha targeted program, enters...
POINT Biopharma to Host Investor Education Event, “Understanding the PNT2002 Phase 3 SPLASH Trial Control Arm”, on August 18, 2022
08 août 2022 08h30 HE
|
POINT Biopharma
The event will prepare investors for the release of SPLASH’s lead-in cohort efficacy data later this year by providing an overview of SPLASH’s trial design. Register online today at...
QSAM Biosciences Receives Third U.S. Patent for Clinical-Stage Radiopharmaceutical Drug Candidate CycloSam®
13 juil. 2022 13h32 HE
|
QSAM Biosciences, Inc.
AUSTIN, Texas, July 13, 2022 (GLOBE NEWSWIRE) -- via Investorwire -- QSAM Biosciences Inc. (OTCQB: QSAM) (the “Company”), a company developing next-generation targeted therapeutic...
POINT Biopharma to Participate in Upcoming Investor Conferences
06 juil. 2022 08h30 HE
|
POINT Biopharma
INDIANAPOLIS, July 06, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to...
POINT Biopharma announces appointment of Chris Horvath as EVP, Commercial
21 juin 2022 08h30 HE
|
POINT Biopharma
Mr. Horvath will lead the commercialization of POINT’s pipeline. He brings over a decade of experience in pharmaceutical commercialization, most recently as the VP and Head of Prostate Cancer...
POINT Biopharma to Participate in Upcoming Investor Conferences
19 mai 2022 17h30 HE
|
POINT Biopharma
INDIANAPOLIS, May 19, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to...
POINT Biopharma Unveils FRONTIER: A Pan-Cancer FAP-α Targeted Clinical Program
16 mai 2022 08h30 HE
|
POINT Biopharma
A No-Objection Letter from Health Canada has been received, enabling the initiation of PNT2004’s Phase 1 therapeutic trial using 68Ga-PNT6555 for imaging and 177Lu-PNT6555 for therapy INDIANAPOLIS,...
POINT Biopharma Reports First Quarter 2022 Financial Results and Provides Business Update
13 mai 2022 08h30 HE
|
POINT Biopharma
POINT's manufacturing facility initiated supply for the Phase 3 SPLASH trial. Randomization of patients for the SPLASH trial expanded to the European Union as scheduled. CTA filed with Health Canada...
Global Peptide Therapeutics Clinical Trials to 2028: Focus on Glucagon-like Peptides, Glycopeptides, Oligopeptides, Lipopeptides, Dipeptides, Opioid, Neuropeptides and Bicyclic Peptides
09 mai 2022 06h28 HE
|
Research and Markets
Dublin, May 09, 2022 (GLOBE NEWSWIRE) -- The "Global Peptide Therapeutics Market & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering. The global peptide...
POINT Biopharma Confirms No Supply Shortages of 177Lu-PNT2002 for the SPLASH Trial
05 mai 2022 09h15 HE
|
POINT Biopharma
INDIANAPOLIS, May 05, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to...